Evidence map›Paper›PMID 20052389›Full record

ArticleInfectious diseases in obstetrics and gynecology2009

HPV prevalence in Colombian women with cervical cancer: implications for vaccination in a developing country.

Raúl Murillo, Mónica Molano, Gilberto Martínez, Juan-Carlos Mejía, Oscar Gamboa

Open access · hybridAbstract read
In one paragraph

Article in Infectious diseases in obstetrics and gynecology, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
1.1field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it, 27 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Raúl MurilloSubdirección Investigaciones, Instituto Nacional de Cancerología de Colombia, Bogota, Colombia. raulhmurillo@yahoo.com
Mónica Molano
Gilberto Martínez
Juan-Carlos Mejía
Oscar Gamboa
Instituto Nacional de Cancerología · COClínica Santa María · CO

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Human Papillomavirus (HPV) vaccines have been considered potentially cost-effective for the reduction of cervical cancer burden in developing countries; their effectiveness in a public health setting continues to be researched. We conducted an HPV prevalence survey among Colombian women with invasive cancer. Paraffin-embedded biopsies were obtained from one high-risk and one low-middle-risk regions. GP5+/GP6+ L1 primers, RLB assays, and E7 type specific PCR were used for HPV-DNA detection. 217 cases were analyzed with 97.7% HPV detection rate. HPV-16/18 prevalence was 63.1%; HPV-18 had lower occurrence in the high-risk population (13.8% versus 9.6%) allowing for the participation of less common HPV types; HPV-45 was present mainly in women under 50 and age-specific HPV type prevalence revealed significant differences. Multiple high-risk infections appeared in 16.6% of cases and represent a chance of replacement. Age-specific HPV prevalence and multiple high-risk infections might influence vaccine impact. Both factors highlight the role of HPVs other than 16/18, which should be considered in cost-effectiveness analyses for potential vaccine impact.

Indexed as

AdultAgedChi-Square DistributionColombiaCross-Sectional StudiesFemaleHuman papillomavirus 16Human papillomavirus 18HumansMiddle AgedPapillomavirus InfectionsPapillomavirus VaccinesPrevalenceStatistics, NonparametricUterine Cervical NeoplasmsPapillomavirus Vaccines

Identifiers

PMID20052389
PMCPMC2801009
OpenAlexW2074351694

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.